Acrobiosystems Co

Acrobiosystems Co ROCE

The Return on Capital Employed (ROCE) of Acrobiosystems Co (301080.SZ) as of Nov 11, 2026 is 7.41 %. In the previous year, Return on Capital Employed (ROCE) was 4.19 % — a change of 76.99% (higher).

ROCE

7.41 %

YoY

76.99%

Last updated:

In 2025, Acrobiosystems Co's return on capital employed (ROCE) was 7.41 %, a 76.99% increase from the 4.19 % ROCE in the previous year.

The Acrobiosystems Co ROCE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROCE
Date
ROCE
Jan 1, 2018
13.90 CNY
Jan 1, 2019
15.66 CNY
Jan 1, 2020
69.97 CNY
Jan 1, 2021
7.96 CNY
Jan 1, 2022
6.45 CNY
Jan 1, 2023
5.12 CNY
Jan 1, 2024
4.19 CNY
Jan 1, 2025
7.41 CNY
The Acrobiosystems Co ROCE history
YEARROCEYoY
7.41 %+76.99%
4.19 %-18.15%
5.12 %-20.66%
6.45 %-19.00%
7.96 %-88.62%
69.97 %+346.78%
15.66 %+12.69%
13.90 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Acrobiosystems Co Stock analysis

What does Acrobiosystems Co do? Acrobiosystems Co Ltd develops biomedicine and bio-protein technology, focusing on recombinant proteins, detection services, kits, antibodies, fillers, and culture media. The company serves R&D and production sectors for drug discovery, screening, diagnostic reagents, and clinical trials across tumor, autoimmune, cardiovascular, and infectious disease areas. Its products support early drug development stages and process control in pharmaceutical manufacturing. The firm's main customers are pharmaceutical companies and research institutions requiring advanced biotech solutions for disease treatment development. The company generates revenue through the sale of recombinant proteins, detection services, and related products like kits and antibodies. These offerings are tailored for pharmaceutical firms engaged in drug development and diagnostic reagent optimization. Acrobiosystems' product portfolio targets the biopharmaceutical industry, specifically addressing needs in tumor, autoimmune, cardiovascular, and infectious disease research. The firm's services are utilized in preclinical and clinical trial phases to enhance drug development efficiency. Acrobiosystems' main products include recombinant proteins, kits, antibodies, fillers, and culture media, which are sold to pharmaceutical companies and research organizations. These entities use the products for early-stage drug discovery, verification, and optimization processes. The company's detection services support diagnostic reagent development and drug screening, directly contributing to the pharmaceutical R&D pipeline. The firm's focus on CMC (process control) for drug production ensures its offerings align with critical manufacturing stages in biopharmaceutical development. Acrobiosystems Co is one of the most popular companies on Eulerpool.

ROCE Details

Unraveling Acrobiosystems Co's Return on Capital Employed (ROCE)

Acrobiosystems Co's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Acrobiosystems Co's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Acrobiosystems Co's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Acrobiosystems Co’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Acrobiosystems Co stock

Return on Capital Employed (ROCE) of Acrobiosystems Co is 7.41 % in 2025.

Return on Capital Employed (ROCE) of Acrobiosystems Co changed from 4.19 % to 7.41 %, representing a 76.99% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Capital Employed (ROCE) Acrobiosystems Co since 2006 – with annual values, charts, and detailed analysis.

ROCE is a profitability measure and stands for Return on Capital Employed or the return on invested capital. The measure shows the ratio of operating profit to the interest-bearing capital employed. The higher the return on capital employed, the more profitable a company operates and the higher the important free cash flow. The free cash flow refers to the portion of profits that is not needed for expanding the company at the end of a period, but is available to shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Capital Employed (ROCE)'s Acrobiosystems Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Capital Employed (ROCE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Capital Employed (ROCE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Acrobiosystems Co

All Key Metrics — Acrobiosystems Co